Literature DB >> 15921208

New immunohistologic findings on the differential role of cyclooxygenase 1 and cyclooxygenase 2 in nasal polyposis.

Jan Gosepath1, Juergen Brieger, Wolf J Mann.   

Abstract

BACKGROUND: Cyclooxygenase 1 (Cox-1) plays a key role in arachidonic acid metabolism and in the pathophysiology and immunology of nasal polyposis in patients suffering from aspirin intolerance. We hypothesize that Cox-2 also might be relevant in the etiology of nasal polyps of aspirin-tolerant patients by their effects on inflammatory mediators as well as on microvascular permeability.
METHODS: Fifty-two surgical specimens were immunohistochemically labeled for Cox-1 and Cox-2. Specimens were taken from chronically inflamed mucosa (n = 19) and from nasal polyps (n = 19) during endonasal sinus surgery. Controls were obtained from healthy nasal respiratory mucosa (n = 14), harvested during turbinate surgery in patients with nasal obstruction without inflammatory disease. Staining intensities were semiquantitatively assessed and statistically analyzed.
RESULTS: In chronically inflamed tissue the expression of Cox-1 and Cox-2 was strongly labeled. However, in nasal polyps the staining pattern of Cox-1 was similar, but Cox-2 expression in epithelial cells was significantly less than in inflamed, nonpolypous specimens.
CONCLUSION: These data suggest that while Cox-1 is strongly up-regulated, Cox-2 expression is significantly lower in epithelial cells of nasal polyps than in those of chronic sinusitis without polyps. The relevance of this finding has to be discussed with respect to the regulatory function of Cox on the inflammatory reaction in nasal respiratory mucosa and its hypothetical role in alterations of capillary permeability via vascular permeability factor/vascular endothelial growth factor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15921208

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  8 in total

1.  Impact of ozone exposure on prostaglandin release in nasal polyps.

Authors:  Cheng Jing Zhu; Kai Fruth; Astrid Schneider; Wolf J Mann; Juergen Brieger
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-12-01       Impact factor: 2.503

Review 2.  Genetics of chronic rhinosinusitis: state of the field and directions forward.

Authors:  Joy Hsu; Pedro C Avila; Robert C Kern; M Geoffrey Hayes; Robert P Schleimer; Jayant M Pinto
Journal:  J Allergy Clin Immunol       Date:  2013-04       Impact factor: 10.793

Review 3.  Factors driving the aspirin exacerbated respiratory disease phenotype.

Authors:  John W Steinke; Larry Borish
Journal:  Am J Rhinol Allergy       Date:  2015 Jan-Feb       Impact factor: 2.467

Review 4.  Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.

Authors:  John W Steinke; Spencer C Payne; Larry Borish
Journal:  Immunol Allergy Clin North Am       Date:  2016-09-13       Impact factor: 3.479

5.  Involvement of B2 receptor in bradykinin-induced proliferation and proinflammatory effects in human nasal mucosa-derived fibroblasts isolated from chronic rhinosinusitis patients.

Authors:  Yih-Jeng Tsai; Sheng-Po Hao; Chih-Li Chen; Brian J Lin; Wen-Bin Wu
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

Review 6.  Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis.

Authors:  Josep M Guilemany; Jordi Roca-Ferrer; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.919

Review 7.  Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances.

Authors:  John W Steinke; Jeff M Wilson
Journal:  J Asthma Allergy       Date:  2016-03-10

8.  Expression of COX-1, COX-2, 5-LOX and CysLT 2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease.

Authors:  Monique Vorsprach; Christoph Arens; Stephan Knipping; Dörte Jechorek; Sabine Stegemann-Koniszewski; Eva Lücke; Jens Schreiber
Journal:  Allergy Asthma Clin Immunol       Date:  2019-12-26       Impact factor: 3.406

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.